Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. METHODS: In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation. RESULTS: At 12 months, the primary end point--a composite of death from vascular causes, myocardial infarction, or stroke--had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 95% confidence interval [CI], 0.77 to 0.92; P<0.001). Predefined hierarchical testing of secondary end points showed significant differences in the rates of other composite end points, as well as myocardial infarction alone (5.8% in the ticagrelor group vs. 6.9% in the clopidogrel group, P=0.005) and death from vascular causes (4.0% vs. 5.1%, P=0.001) but not stroke alone (1.5% vs. 1.3%, P=0.22). The rate of death from any cause was also reduced with ticagrelor (4.5%, vs. 5.9% with clopidogrel; P<0.001). No significant difference in the rates of major bleeding was found between the ticagrelor and clopidogrel groups (11.6% and 11.2%, respectively; P=0.43), but ticagrelor was associated with a higher rate of major bleeding not related to coronary-artery bypass grafting (4.5% vs. 3.8%, P=0.03), including more instances of fatal intracranial bleeding and fewer of fatal bleeding of other types. CONCLUSIONS: In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding. (ClinicalTrials.gov number, NCT00391872.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with ACS undergoing PCI, 12 months' DAPT with low-dose ASA and prasugrel or ticagrelor was superior to DAPT with clopidogrel in the diabetes sub-group of the respective RCTs, with a benefit-risk profile similar to the overall trial populations (Supplementary data online, Tables S12-13).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [311]
In the citing paper
“In patients with ACS for whom an early invasive strategy is planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin was superior to clopidogrel and aspirin.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [503]
In the citing paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [503]
In the citing paper
“International trials of various pharmacotherapies have sometimes found discordant results in patients enrolled in the United States than seen in overall trial results.19–32”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [19]
In the citing paper
“The reasons range from low numbers of patients enrolled in the United States to potential differences in background medical management or in patient risk profiles.”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [19]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationBraunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Mehta, S. R., Yusuf, S., Peters, R. J., Bertrand, M. E., Lewis, B. S., Natarajan, M. K., Malmberg, K., Rupprecht, H.-J., Zhao, F., Chrolavicius, S., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05701-4 · Cited by 2,809
急性心筋梗塞の疑いのある17187症例におけるストレプトキナーゼ静脈内投与,アスピリン経口投与,上記2つの併用または無処置の無作偽試験 ISIS-2
Dienstl, F., Backer, G. D., Cairns, J., Pedersen, F., Kala, R., Boissel, J., Schroeder, R., Horgan, J., & Tognoni, G. (1988) · The Lancet · Cited by 2,754
Mehta, S. R., Yusuf, S., & Peters, R. J. G. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00559-7 · Cited by 2,578
Research works printed but not linked: 2
- 10.1016/S0140-6736(01)05701-4 · DOI · Paper page
- 1988, Lancet, 2, 349
Cited by
Items 901–1,000 of 1,005
Schiele, F., Ecarnot, F., & Chopard, R. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317706586 · Cited by 60
Diabetes and antiplatelet therapy: from bench to bedside
Rios, J. R. R., Franchi, F., Rollini, F., & Angiolillo, D. J. (2018) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2018.05.09 · Cited by 59
Modern Management of ST-Segment Elevation Myocardial Infarction
Frampton, J., DeVries, J. T., Welch, T. D., & Gersh, B. J. (2018) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2018.08.005 · Cited by 55
van Leeuwen, M. A. H., van der Hoeven, N. W., Janssens, G. N., Everaars, H., Nap, A., Lemkes, J. S., de Waard, G. A., van de Ven, P. M., van Rossum, A. C., Ten Cate, T. J. F., et al. (2019) · doi:10.7892/boris.124089 · Cited by 52
Nakamura, M., Kadota, K., Takahashi, A., Kanda, J., Anzai, H., Ishii, Y., Shibata, Y., Yasaka, Y., Takamisawa, I., Yamaguchi, J., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015439 · Cited by 52
Frailty in Acute and Chronic Coronary Syndrome Patients Entering Cardiac Rehabilitation
Giallauria, F., Lorenzo, A. D., Venturini, E., Pacileo, M., D’Andrea, A., Garofalo, U., Lucia, F. D., Testa, C., Cuomo, G., Iannuzzo, G., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081696 · Cited by 56
“In patients after ACS undergoing PCI, standard 12 months dual antiplatelet therapy (DAPT) (aspirin plus P2Y12-receptor inhibitors) is usually recommended [60] aiming at reducing 1-year atherothrombotic events [67].”
BackgroundShin, D., Kang, H., Jang, J., Moon, K., Song, Y. B., Park, D., Bae, J., Kim, J., Hur, S., Kim, B. O., et al. (2019) · Korean Circulation Journal · doi:10.4070/kcj.2018.0413 · Cited by 52
Emre, A., Terzi, S., Çeliker, E., Şahin, S., Yazıcı, S., Erdem, A., Ceylan, U. S., Aşık, M., & YEŞİLÇİMEN, K. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.09.021 · Cited by 52
Do Current Clinical Trials Meet Society’s Needs?
Pocock, S., & Gersh, B. J. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.08.008 · Cited by 51
French, S. L., Arthur, J. F., Tran, H. A., & Hamilton, J. R. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.10.006 · Cited by 51
Triple Therapy for Atrial Fibrillation and Percutaneous Coronary Intervention
Dewilde, W. J. M., Janssen, P. W. A., Verheugt, F. W. A., Storey, R. F., Adriaenssens, T., Hansen, M. L., Lamberts, M., & ten Berg, J. M. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1193 · Cited by 53
Self-citationKoutouzis, M., Lagerqvist, B., James, S. K., Ömerovic, E., Matejka, G., Grip, L., & Albertsson, P. (2011) · Heart · doi:10.1136/hrt.2011.224709 · Cited by 51
Self-citationBleeding Complications in Patients Undergoing Percutaneous Coronary Intervention
Galli, M., Laborante, R., Andreotti, F., Vergallo, R., Montone, R. A., Iaconelli, A., Trani, C., Burzotta, F., Crea, F., & D’Amario, D. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2308286 · Cited by 62
“Prasugrel and ticagrelor are characterized by more potent and predictable pharmacodynamic effects compared with clopidogrel, which however lead to an increased risk of bleeding [105,106].”
BackgroundVelders, M. A., Wallentin, L. C., Becker, R. C., van Boven, A. J., Himmelmänn, A., Husted, S., Katus, H. A., Lindholm, D. P., Morais, J., Siegbahn, A. G., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.02.019 · Cited by 52
Self-citationBasra, S. S., Tsai, P. I.-H., & Lakkis, N. M. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.051 · Cited by 58
Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors
Koziński, M., Ostrowska, M., Fabiszak, T., Navarese, E. P., Paciorek, P., Grześk, G., Kubica, J., & Adamski, P. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-11-0915 · Cited by 51
Hansson, E. C., Rexius, H., Dellborg, M., Albertsson, P., & Jeppsson, A. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezt662 · Cited by 55
New Approaches to Inhibiting Platelets and Coagulation
Depta, J. P., & Bhatt, D. L. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124438 · Cited by 55
Patil, S. B., Jackman, L. E., Francis, S., Judge, H. M., Nylander, S., & Storey, R. F. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.210732 · Cited by 51
Self-citationPersonalized antiplatelet therapy with P2Y 12 receptor inhibitors: benefits and pitfalls
Winter, M., Koziński, M., Kubica, J., Aradi, D., & Siller-Matula, J. M. (2015) · Advances in Interventional Cardiology · doi:10.5114/pwki.2015.55596 · Cited by 54
Chung, S., Tong, M., Sheu, J., Lee, F.-Y., Sung, P., Chen, C.-J., Yang, C., Wu, C., & Yip, H. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.08.068 · Cited by 53
Abtan, J., Steg, P. G., Stone, G. W., Mahaffey, K. W., Gibson, C. M., Hamm, C. W., Price, M. J., Abnousi, F., Prats, J., Deliargyris, E., et al. (2016) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2016.06.046 · Cited by 60
Self-citationVaduganathan, M., Harrington, R. A., Stone, G. W., Deliargyris, E., Steg, P. G., Gibson, C. M., Hamm, C. W., Price, M. J., Menozzi, A., Prats, J., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4556 · Cited by 51
Self-citationHow I use laboratory monitoring of antiplatelet therapy
Michelson, A. D., & Bhatt, D. L. (2017) · Blood · doi:10.1182/blood-2017-03-742338 · Cited by 56
“agent is mandatory, and in the ACS patient this can be clopidogrel, prasugrel, or ticagrelor.(3,4,6) This dual antiplatelet therapy (DAPT) should be continued for at least a year unlessmajor bleeding issues arise.”
BackgroundDoğanay, Ö., Atalay, B., Karadag, E., Aga, U., & Tuğrul, M. (2018) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2017.09.052 · Cited by 52
Antunes, M. M., Duarte, G. S., Brito, D. A., Borges, M., Costa, J. N., Ferreira, J. J., Pinto, F. J., & Caldeira, D. (2020) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaa030 · Cited by 62
Galli, M., Franchi, F., Rollini, F., & Angiolillo, D. J. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.007 · Cited by 54
Montalescot, G., Lassen, J. F., Hamm, C. W., Lapostolle, F., Silvain, J., ten Berg, J. M., Cantor, W. J., Goodman, S. G., Licour, M., Tsatsaris, A., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2012.12.015 · Cited by 50
Tavenier, A. H., Mehran, R., Chiarito, M., Cao, D., Pivato, C. A., Nicolas, J., Beerkens, F., Nardin, M., Sartori, S., Baber, U., et al. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab068 · Cited by 57
Li, H., Butler, K. A., Li, Y., Yang, Z., & Teng, R. (2011) · Clinical Drug Investigation · doi:10.2165/11595930-000000000-00000 · Cited by 50
Intra-Procedural Stent Thrombosis
Brener, S. J., Cristea, E., Kirtane, A. J., McEntegart, M. B., Xu, K., Mehran, R., & Stone, G. W. (2012) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2012.08.018 · Cited by 50
Kim, I., Jeong, Y., Park, Y., Park, K., Yun, S.-E., Park, J. R., Hwang, S., Koh, E., Kwak, C. H., Hwang, J., et al. (2011) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.12.010 · Cited by 50
Genetic determinants of on-clopidogrel high platelet reactivity
Campo, G. C., Miccoli, M., Tebaldi, M., Marchesini, J., Fileti, L., Monti, M., Valgimigli, M., & Ferrari, R. (2011) · Platelets · doi:10.3109/09537104.2011.579648 · Cited by 50
Tobacco and Cardiovascular Health
Mainali, P., Pant, S., Rodríguez, A., Deshmukh, A. J., & Mehta, J. L. (2014) · Cardiovascular Toxicology · doi:10.1007/s12012-014-9280-0 · Cited by 56
Weitz, J. I. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-03-0265 · Cited by 56
Jaffe, T. A., Raiff, D., Ho, L. M., & Kim, C. (2015) · American Journal of Roentgenology · doi:10.2214/ajr.14.13342 · Cited by 50
Thrombus aspiration in acute myocardial infarction
Mahmoud, K. D., & Zijlstra, F. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.38 · Cited by 50
Khan, J. N., Greenwood, J. P., Nazir, S. A., Lai, F. Y., Dalby, M. C. D., Curzen, N. P., Hetherington, S. L., Kelly, D. J., Blackman, D. J., Peebles, C., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003403 · Cited by 50
Lee, C., Cheng, C., Yang, Y. K., Chao, T., Chen, J., & Li, Y. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0632 · Cited by 51
Bagai, A., Wang, Y., Wang, T. Y., Curtis, J. P., Gurm, H. S., Shah, B., Cheema, A. N., Peterson, E. D., Saucedo, J. F., Granger, C. B., et al. (2014) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.001555 · Cited by 50
Caldeira, D., Rodrigues, B. K. A. B., David, C., Costa, J. N., Pinto, F. J., & Ferreira, J. J. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1690459 · Cited by 57
“Secondly, the lethal cases are excluded and a fraction of 4–6% of the patients may be missed [24,25].”
BackgroundKan, P., Sweid, A., Srivatsan, A., & Jabbour, P. M. (2019) · Neurosurgery · doi:10.1093/neuros/nyz304 · Cited by 50
Magavern, E. F., Kaski, J. C., Turner, R. M., Drexel, H., Janmohamed, A., Scourfield, A., Burrage, D., Floyd, C. N., Adeyeye, E., Tamargo, J. L., et al. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab018 · Cited by 62
“potent P2Y12 receptor antagonists, prasugrel, and ticagrelor, are usually preferred over clopidogrel in high-risk cases on the basis of improved cardiovascular outcomes, albeit with an increased bleeding risk.(47) In stroke, single-antiplatelet therapy with clopidogrel alone is usually preferred for long-term secondar…”
BackgroundGalli, M., Franchi, F., Rollini, F., Cavallari, L. H., Capodanno, D., Crea, F., & Angiolillo, D. J. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1927709 · Cited by 52
“In the Study of Platelet Inhibition and Patient Outcomes (PLATO) trial, 18,624 patients with ACS (unstable angina, NSTEMI, and STEMI) were randomly assigned to receive either ticagrelor (180 mg loading dose followed by 90 mg twice daily maintenance dose) or clopidogrel (300–600 mg loading dose followed by 75 mg daily…”
BackgroundMethodInfluentialNergiz‐Unal, R., Cosemans, J. M. E. M., Feijge, M. A. H., van der Meijden, P. E. J., Storey, R. F., van Giezen, J. J. J., Egbrink, M. G. A. O., Heemskerk, J. W. M., & Kuijpers, M. J. E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010130 · Cited by 50
Self-citationDamman, P., Varenhorst, C., Koul, S. M., Eriksson, P., Erlinge, D., Lagerqvist, B., & James, S. K. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.09.019 · Cited by 49
Self-citationPharmacology and clinical trials of reversibly-binding P2Y12 inhibitors
Storey, R. F. (2011) · Thrombosis and Haemostasis · doi:10.1160/ths10-12-0769 · Cited by 50
Self-citationAntithrombotic therapy for acute coronary syndrome: Past, present and future
Sibbing, D., Angiolillo, D. J., & Huber, K. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-12-0963 · Cited by 52
“Still, aspirin is a cornerstone of treatment and based on the results of TRITON-TIMI 38 (39) and PLATO (49), the two potent ADP receptor inhibitors (prasugrel and ticagrelor) are now approved and established for ACS treatment.”
BackgroundMethodTao, S., Tang, X., Yu, L., Li, L., Zhang, G., Zhang, L., Huang, L., & Wu, J. (2023) · European journal of medical research · doi:10.1186/s40001-023-01220-5 · Cited by 63
“…[26]), 6 clinical trials (3 randomized controlled trials on the efficacy of anti-coagulant/ anti-platelet drugs in acute coronary syndromes [27–29], 2 multi-center randomized controlled trial of the efficacy and safety of stent implantation [30, 31], 1 randomized controlled trial comparing…”
BackgroundFerreiro, J. L., Bhatt, D. L., Ueno, M., Bauer, D., & Angiolillo, D. J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.043 · Cited by 52
Teng, R., & Butler, K. A. (2013) · Journal of Drug Assessment · doi:10.3109/21556660.2013.785413 · Cited by 49
Vein graft failure: current clinical practice and potential for gene therapeutics
Wan, S., George, S. J., Berry, C., & Baker, A. H. (2012) · Gene Therapy · doi:10.1038/gt.2012.29 · Cited by 58
Role of Platelets and Antiplatelet Therapy in Cardiovascular Disease
Ueno, M., Kodali, M. K., Tello‐Montoliu, A., & Angiolillo, D. J. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.7633 · Cited by 53
The Case for Routine Genotyping in Dual-Antiplatelet Therapy
Damani, S. B., & Topol, E. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.029 · Cited by 49
Schuette, C., Steffens, D., Witkowski, M., Stellbaum, C., Bobbert, P., Schultheiss, H.-P., & Rauch, U. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0182-7 · Cited by 49
Servi, S. D., Gödicke, J., Schirmer, A., & Widimský, P. (2014) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872614534078 · Cited by 49
Single or dual antiplatelet therapy after PCI
Miyazaki, Y., Suwannasom, P., Sotomi, Y., Abdelghani, M., Tummala, K., Katagiri, Y., Asano, T., Tenekecioğlu, E., Zeng, Y., Cavalcante, R., et al. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.12 · Cited by 49
Zanchin, T., Temperli, F., Karagiannis, A., Zanchin, C., Räsänen, M., Koskinas, K. C., Stortecky, S., Hunziker, L., Praz, F., Blöchlinger, S., et al. (2018) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.117.006132 · Cited by 54
Choi, S. Y., Kim, M. H., Cho, Y., Park, J. S., Lee, K. M., Park, T., & Yun, S. (2018) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.118.006837 · Cited by 49
Bleeding in Patients Treated With Ticagrelor or Clopidogrel Before Coronary Artery Bypass Grafting
Holm, M., Biancari, F., Khodabandeh, S., Gherli, R., Airaksinen, J. K. E., Mariscalco, G., Gatti, G., Reichart, D., Onorati, F., FEO, M. D., et al. (2019) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2019.01.086 · Cited by 49
Schmucker, J., Fach, A., Marín, L. A. M., Retzlaff, T., Osteresch, R., Kollhorst, B., Hambrecht, R., Pohlabeln, H., & Wienbergen, H. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012530 · Cited by 53
“However, elderly patients were underrepresented in the TRITON TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38) and PLATO trials, composing only 13% and 15% of the study populations, respectively.(2,3) This is especia…”
Wang, Y., Johnston, S. C., Bath, P. M., Meng, X., Jing, J., Xie, X., Wang, A., Pan, Y., Xu, A., Dong, Q., et al. (2021) · Stroke and Vascular Neurology · doi:10.1136/svn-2020-000791 · Cited by 49
Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective
Mangieri, A., Gallo, F., Sticchi, A., Khokhar, A. A., Laricchia, A., Giannini, F., & Colombo, A. (2020) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-020-00642-w · Cited by 52
Trends of Sex Differences in Clinical Outcomes After Myocardial Infarction in the United States
Matetić, A., Shamkhani, W., Rashid, M. O., Volgman, A. S., Spall, H. G. C. V., Coutinho, T. A., Mehta, L. S., Sharma, G. V., Parwani, P. J., Mohamed, M., et al. (2021) · CJC Open · doi:10.1016/j.cjco.2021.06.012 · Cited by 55
“Additionally, superiority of potent purinergic receptor P2Y12 inhibitors against thrombotic events in PCIs has been shown in trials.(49) However, studies suggested underuse in women.”
BackgroundDual Antiplatelet Therapy: A Concise Review for Clinicians
Virk, H. U. H., Escobar, J., Rodríguez, M., Bates, E., Khalid, U., Jneid, H. M., Birnbaum, Y., Levine, G. N., Smith, S. C., & Krittanawong, C. (2023) · Life · doi:10.3390/life13071580 · Cited by 63
“Ticagrelor had similar bleeding risk but more dyspnea and ventricular pauses compared to clopidogrel [20].”
BackgroundFactor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism
Capodanno, D., Alexander, J. H., Bahit, M. C., Eikelboom, J. W., Gibson, C. M., Goodman, S. G., Kunadian, V., Lip, G. Y. H., Lópes, R. D., Mehran, R., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01144-z · Cited by 57
Self-citationApixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes
Hess, C. N., James, S. K., Lópes, R. D., WOJDYLA, D. M., Neely, M. L., Liaw, D., Hagström, E., Bhatt, D. L., Husted, S., Goodman, S. G., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.027 · Cited by 51
Self-citationTeng, R., Mitchell, P., & Butler, K. A. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12130 · Cited by 48
Managing antiplatelet and anticoagulant drugs in patients undergoing elective ophthalmic surgery
Kiire, C. A., Mukherjee, R., Ruparelia, N., Keeling, D. M., Prendergast, B., & Norris, J. H. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-304902 · Cited by 47
Ueno, M., Ferreiro, J. L., Desai, B., Tomasello, S. D., Tello‐Montoliu, A., Capodanno, D., Capranzano, P., Kodali, M. K., Dharmashankar, K., Charlton, R. K., et al. (2012) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2011.09.027 · Cited by 53
Komócsi, A., Vorobcsuk, A., Serebruany, V. L., & Aradi, D. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-06-0377 · Cited by 48
Qaderdan, K., Ishak, M., Heestermans, A. A. C. M., de Vrey, E. A., Jukema, J. W., Voskuil, M., de Boer, M., Hof, A. W. J. V. ’., Groenemeijer, B. E., Vos, G.-J. A., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.07.030 · Cited by 48
Traby, L., Kollars, M., Kaider, A., Eichinger, S., Wolzt, M., & Kyrle, P. A. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13216 · Cited by 48
Sahlén, A., Varenhorst, C., Lagerqvist, B., Renlund, H., Wallentin, L. C., James, S. K., & Jernberg, T. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv034 · Cited by 48
Self-citationBleeding Avoidance Strategies During Percutaneous Coronary Interventions
Singh, M. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.567 · Cited by 48
Wang, H., & Wang, X. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s108965 · Cited by 48
Teng, R., Carlson, G. F., Nylander, S., & Andersson, T. L. G. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13511 · Cited by 48
Dual Antiplatelet Therapy in Coronary Artery Disease
Sharma, R., Kumar, P., Prashanth, S. P., & Belagali, Y. R. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00197-0 · Cited by 58
Lee, C. R., Thomas, C. D., Beitelshees, A. L., Tuteja, S., Empey, P. E., Lee, J. C., Limdi, N. A., Duarte, J. D., Skaar, T. C., Chen, Y., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2039 · Cited by 54
“In contrast, CYP2C19 genotype does not impact the clinical effects of prasugrel or ticagrelor,(6,7) which exhibit more consistent antiplatelet effects, superior efficacy in acute coronary syndrome (ACS) patients in the absence of CYP2C19 genotyping, and higher bleeding risk compared with clopidogrel.(8,9) Accumulating…”
BackgroundBerger, J. S., Katona, B. G., Jones, W. S., Patel, M. R., Norgren, L., Baumgartner, I., Blomster, J., Mahaffey, K. W., Held, P., Millegård, M., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.01.018 · Cited by 47
Self-citationStavrou, K., Koniari, I. C., Gkizas, V., Perperis, A., Κοντοπρίας, Κ., Vogiatzi, C., Bampouri, T., Xanthopoulou, I., & Alexopoulos, D. K. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-02-0119 · Cited by 49
Carvalho, P. E. P., Gewehr, D. M., Nascimento, B. R., Melo, L., Burkhardt, G., Rivera, A., Braga, M. A. P., Guimarães, P. O., Mehran, R., Windecker, S., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.3216 · Cited by 56
Dang, Q., Psaltis, P. J., Burgess, S. N., Chandrasekhar, J., Mukherjee, S., Kritharides, L., Jepson, N. S., Fairley, S. L., Ihdayhid, A. R., Layland, J. J., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf097 · Cited by 54
“28 Given that the underlying pathology in SCAD is usually an intramural haematoma, anticoagulation and/or more potent P2Y 12 inhibition may be harmful.”
Udell, J. A., D, E. B. M., Antman, E. M., Murphy, S. A., Montalescot, G., & Wiviott, S. D. (2014) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.01.160 · Cited by 47
Genetics of platelet inhibitor treatment
Trenk, D., & Hochholzer, W. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12230 · Cited by 47
Butler, K. A., & Teng, R. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011415526 · Cited by 51
Butler, K. A., & Teng, R. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010379409 · Cited by 49
Valgimigli, M. (2014) · Circulation · doi:10.1161/circulationaha.114.011319 · Cited by 47
Acute Coronary Syndrome Among Older Patients: A Review
Veerasamy, M., Edwards, R., Ford, G. A., Kirkwood, T. B. L., Newton, J. L., Jones, D. E., & Kunadian, V. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000016 · Cited by 54
Clinical Trial Participation After Myocardial Infarction in a National Cardiovascular Data Registry
Udell, J. A., Wang, T. Y., Li, S., Kohli, P., Roe, M. T., de Lemos, J. A., & Wiviott, S. D. (2014) · JAMA · doi:10.1001/jama.2014.6217 · Cited by 47
Jeong, K. H., Cho, J. H., Woo, J. S., Kim, J., Kim, W.-S., Lee, T. W., Kim, K. S., Ihm, C. G., & Kim, W. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.11.023 · Cited by 47
Tricoci, P., Leonardi, S., White, J. A., White, H. D., Armstrong, P. W., Montalescot, G., Giugliano, R. P., Gibson, C. M., de Werf, F. V., Califf, R. M., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.04.043 · Cited by 49
Self-citationPaikin, J. S., Wright, D. S., & Eikelboom, J. W. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.01.007 · Cited by 48
Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges
Cherepanov, V., Cabrera-Fuentes, H. A., Kim, M. H., & Serebruany, V. L. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-01-0077 · Cited by 48
Current status of data on cangrelor
Qamar, A., & Bhatt, D. L. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.004 · Cited by 48
Gwon, H., Jeon, D. W., Kang, H., Jang, J., Park, D., Shin, D., Moon, K., Kim, J., Kim, J. H., Bae, J., et al. (2017) · Korean Circulation Journal · doi:10.4070/kcj.2017.0070 · Cited by 47
Feres, F., Ra, C., Siqueira, D., Costa, J., Jr., Chamié, D., Staico, R., Aj, C., Abizaid, A., Marin‐Neto, J. A., Rassi, A., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170111 · Cited by 58
Franchi, F., James, S. K., Lakic, T. G., Budaj, A., Cornel, J. H., Katus, H. A., Keltai, M., Kontny, F. P., Lewis, B. S., Storey, R. F., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011139 · Cited by 55
“Ticagrelor is characterized by more potent and predictable antiplatelet effects compared with clopidogrel, which translate into better clinical outcomes in ACS patients, albeit at the expense of an increased risk of major bleeding.(22,37) Pharmacodynamic assessments have shown that the enhanced potency of ticagrelor o…”
MethodInfluentialSelf-citationLimdi, N. A., Cavallari, L. H., Lee, C. R., Hillegass, W. B., Holmes, A. M., Skaar, T. C., Pisu, M., Dillon, C., Beitelshees, A. L., Empey, P. E., et al. (2020) · The Pharmacogenomics Journal · doi:10.1038/s41397-020-0162-5 · Cited by 52
Acute Coronary Syndrome: Focus on Antiplatelet Therapy
Bobadilla, R. V. (2016) · Critical Care Nurse · doi:10.4037/ccn2016497 · Cited by 15
Metadata
- Authors
- Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., Mahaffey, K. W., Scirica, B. M., Skene, A., Steg, P. G., Storey, R. F., & Harrington, R. A.
- Affiliations
- Uppsala University (SE)
- Duke Clinical Research Institute (US)
- Grochowski Hospital (PL)
- Brigham and Women's Hospital (US)
- AstraZeneca (Sweden) (SE)
- Aarhus University Hospital (DK)
- University Hospital Heidelberg (DE)
- University of Sheffield (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-09-10
- Volume
- 361
- Issue
- 11
- Pages
- 1045-1057
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140501627
- Cited by
- 7,117
- References
- 35
- Citations by year
- 2026: 214 · 2025: 277 · 2024: 267 · 2023: 359 · 2022: 411 · 2021: 454 · 2020: 500 · 2019: 472 · 2018: 473 · 2017: 480 · 2016: 494 · 2015: 522 · 2014: 467 · 2013: 520 · 2012: 464
- FWCI
- 253.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- ticagrelor, clopidogrel, acute coronary syndrome, ST-elevation myocardial infarction, P2Y12 inhibitors, platelet aggregation inhibition, major adverse cardiovascular events, major bleeding, intracranial hemorrhage, myocardial infarction, vascular death, stroke, dual antiplatelet therapy, antiplatelet therapy, drug safety and efficacy comparison
- MeSH terms
- Clopidogrel, Ticagrelor, Adenosine, Aged, Double-Blind Method, Dyspnea, Electrocardiography, Female, Hemorrhage, Humans, Male, Myocardial Infarction, Platelet Aggregation Inhibitors, Ticlopidine, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.